Celularity ( (CELU) ) has released a notification of late filing.
Celularity Inc. has filed a Form 12b-25, indicating a delay in submitting its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to constraints in the company’s liquidity position and financial accounting staffing levels, which have impacted the financial close and reporting process. Celularity anticipates filing the report within the 15-day extension period allowed by the SEC. The company expects significant changes in its financial results, with total net revenues anticipated to increase by 138.1% to $54.2 million, driven by sales of Biovance 3L and Rebound. Operating expenses are expected to decrease by 57.4% due to the absence of impairment charges that were present in the previous year. Celularity is committed to resolving these issues and ensuring compliance, as indicated by the signature of David C. Beers, Chief Financial Officer, on the notification.
More about Celularity
YTD Price Performance: -19.41%
Average Trading Volume: 161,286
Technical Sentiment Signal: Buy
Current Market Cap: $42.21M
For a thorough assessment of CELU stock, go to TipRanks’ Stock Analysis page.